Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574642 | 0.88 | NAMPT (0.48) | TDP1HTTNAMPT | |
| SCHEMBL1574970 | 0.81 | LMNA (0.43) | LMNAKMT2ANPSR1TDP1CYP2C19 | |
| SCHEMBL1574449 | 0.80 | LMNA (0.47) | LMNAKMT2ANPSR1TDP1CYP2C19 | |
| SCHEMBL1574649 | 0.79 | LMNA (0.46) | LMNAKMT2ANPSR1TDP1CYP2C19 | |
| SCHEMBL1574751 | 0.78 | ALDH1A1 (0.48) | KMT2ANPSR1CYP2C19MEN1CYP2C9 | |
| SCHEMBL1574915 | 0.74 | ADAM17 (0.50) | HTTNAMPT | |
| SCHEMBL1575097 | 0.74 | KDM4E (0.52) | KMT2ANPSR1MEN1 | |
| SCHEMBL25853767 | 0.71 | LMNA (0.48) | LMNAKMT2ANPSR1CYP2C19HTT | |
| SCHEMBL25849283 | 0.71 | LMNA (0.48) | LMNAKMT2ANPSR1CYP2C19HTT | |
| SCHEMBL4089086 | 0.71 | LMNA (0.51) | LMNAKMT2ANPSR1TDP1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308562-A2 | Azetidine ring compounds and drugs comprising the same | Ono Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7511159-B2 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-03-31 | — | — | US | disclosed |
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-14 | — | — | US | disclosed |
| EP-1698375-A1 | AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135402-A1 | Azetidine ring compounds and drugs comprising the same | EDNRA, LIPG, EDNRB | LMNA 1076/4885KMT2A 2539/4885NPSR1 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.